Faeth Therapeutics, Inc（FTH）财务数据FTHFaeth Therapeutics, Inc

Evaluating the bottom line, Faeth Therapeutics, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -195.26%, provide a clear picture of how effectively FTH converts its operational activities into shareholder value.

In the context of the broader market, FTH competes directly with industry leaders such as VALN and AGMB. With a market capitalization of $441.35M, it holds a significant position in the sector. When comparing efficiency, FTH's gross margin of N/A stands against VALN's 9.60% and AGMB's N/A. Such benchmarking helps identify whether Faeth Therapeutics, Inc is trading at a premium or discount relative to its financial performance.

Faeth Therapeutics has experienced a significant net loss of $16 million in Q2 2026, with an EPS of -2.84, indicating challenges in profitability. However, the company has improved its cash position to $186.4 million, which supports ongoing research and development efforts.